Volume 15 Supplement 1

Targeted Temperature Management (TTM 2014)

Open Access

Let’s get started with targeted temperature management

  • Fabio Silvio Taccone1
BMC Emergency Medicine201515(Suppl 1):A1

https://doi.org/10.1186/1471-227X-15-S1-A1

Published: 24 June 2015

Cardiac arrest (CA) remains a major cause of death and severe disability worldwide. The ischemic process that follows the cessation of cerebral perfusion and oxygenation, which is further worsened by the reperfusion injury occurring after the return of spontaneous circulation, can lead to severe hypoxic brain damage, resulting in a high rate of poor neurological recovery among CA survivors.

The use of mild therapeutic hypothermia, or targeted temperature management (TTM) as recently suggested [1], has been recommended in CA patients since the publication of two randomized clinical trials in 2002, the results of which demonstrated a significant improvement in neurologically intact survival for comatose CA patients presenting with ventricular fibrillation or ventricular tachycardia [1, 2]. Current guidelines suggest that mild therapeutic hypothermia should also be considered in patients presenting with other rhythms, although this has been less well studied [3].

In experimental studies, TTM provided significant cardiac and neurological protective effects through different pathways. Hypothermic mechanisms providing myocardial protection include, amongst all, improved energy production during ischemia, increased calcium sensitivity of myocytes, regulation of mitochondrial oxidative phosphorylation and preserved myocardial vascular autoregulation [4, 5]. All of these protective mechanisms would result in increased myocardial contractility. After a post-anoxic injury, TTM may also protect cerebral function through reduced release of excitatory (that is, glutamate and dopamine) neurotransmitters, attenuation of reactive oxygen species production, preservation of the blood–brain barrier, protection of cerebral microcirculation and decrease in intracranial pressure [6, 7]. As several pathways are involved in the pathogenesis of extended post-anoxic brain damage, TTM can be considered as a general and nonspecific neuroprotective strategy, which may efficiently attenuate and mitigate most of these mechanisms and potentially improve patients’ neurological outcome. Interestingly, recent studies have underlined not only that the hypothermic phase is important in this process, but that strict control of the patient’s temperature during the first 3 days since hospital admission (that is, rapid achievement of target temperature, a precise control of temperature during the maintenance phase, a slow and controlled rewarming and avoidance of fever for 48 to 72 hours) are key components to enhance TTM effectiveness after post-anoxic brain injury [8].

Financial disclosure

FST received a research grant from Benechill in 2010 for animal research on IAHT.

Declarations

Declaration

This abstract and supplement was proposed, developed and commissioned by BMC Emergency Medicine and was funded by an educational grant from C. R. BARD, NJ, USA. The published abstract was independently prepared by the author. C. R. BARD had no input into the content.

Authors’ Affiliations

(1)
Department of Intensive Care, Hopital Erasme, Université Libre de Bruxelles

References

  1. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002, 346 (8): 557-563. 10.1056/NEJMoa003289.View ArticlePubMedGoogle Scholar
  2. Hypothermia after Cardiac Arrest Study Group: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002, 346 (8): 549-556.View ArticleGoogle Scholar
  3. Deakin CD, Nolan JP, Soar J, Sunde K, Koster RW, Smith GB, et al: European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support. Resuscitation. 2010, 81 (10): 1305-1352. 10.1016/j.resuscitation.2010.08.017.View ArticlePubMedGoogle Scholar
  4. Ning XH, Chen SH, Xu CS, Hyyti OM, Qian K, Krueger JJ, et al: Hypothermia preserves myocardial function and mitochondrial protein gene expression during hypoxia. Am J Physiol Heart Circ Physiol. 2003, 285 (1): H212-H219. 10.1152/ajpheart.01149.2002.View ArticlePubMedGoogle Scholar
  5. Ristagno G, Tantillo S, Sun S, Weil MH, Tang W: Hypothermia improves ventricular myocyte contractility under conditions of normal perfusion and after an interval of ischemia. Resuscitation. 2010, 81 (7): 898-903. 10.1016/j.resuscitation.2010.03.016.View ArticlePubMedGoogle Scholar
  6. Karibe H, Zarow GJ, Graham SH, Weinstein PR: Mild intraischemic hypothermia reduces postischemic hyperperfusion, delayed postischemic hypoperfusion, blood–brain barrier disruption, brain edema, and neuronal damage volume after temporary focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1994, 14 (4): 620-627. 10.1038/jcbfm.1994.77.View ArticlePubMedGoogle Scholar
  7. Takasu A, Yagi K, Okada Y: Effect of mild hypothermia on ischemia-induced release of endothelin-1 in dog brain. Resuscitation. 1996, 31 (1): 59-64. 10.1016/0300-9572(95)00907-8.View ArticlePubMedGoogle Scholar
  8. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al: Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013, 369 (23): 2197-206. 10.1056/NEJMoa1310519.View ArticlePubMedGoogle Scholar

Copyright

© Taccone; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement